JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hashizume, T.
Right arrow Articles by Funae, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hashizume, T.
Right arrow Articles by Funae, Y.

Vol. 300, Issue 1, 298-304, January 2002

Involvement of CYP2J2 and CYP4F12 in the Metabolism of Ebastine in Human Intestinal Microsomes

Takanori Hashizume, Susumu Imaoka, Masashi Mise, Yoshiaki Terauchi, Toshihiko Fujii, Hisashi Miyazaki, Tetsuya Kamataki and Yoshihiko Funae

Pharmacokinetics and Physico-Chemical Property Research Laboratories, Dainippon Pharmaceutical Company, Ltd., Osaka, Japan (T.H., M.M., Y.T., T.F., H.M.); Department of Chemical Biology, Osaka City University Medical School, Osaka, Japan (S. I., Y.F.); and Laboratory of Drug Metabolism, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan (T.K.)

The purpose of the study was to elucidate human intestinal cytochrome P450 isoform(s) involved in the metabolism of an antihistamine, ebastine, having two major pathways of hydroxylation and N-dealkylation. The ebastine dealkylase in human intestinal microsomes was CYP3A4, based on the inhibition studies with antibodies against CYP1A, CYP2A, CYP2C, CYP2D, CYP2E, and CYP3A isoforms and their selective inhibitors. However, ebastine hydroxylase could not be identified. We then examined the inhibitory effects of anti-CYP4F antibody and 17-octadecynoic acid, an inhibitor of the CYP4 family, on ebastine hydroxylation in intestinal microsomes, since CYP4F was recently found to be the predominant ebastine hydroxylase in monkey intestine; and a novel CYP4F isoform (CYP4F12), also capable of hydroxylating ebastine, was found to exist in human intestine. However, the inhibitory effects were only partial (about 20%) and thus it was thought that, although human CYP4F was involved in ebastine hydroxylation, another predominant enzyme exists. Further screening showed that the hydroxylation was inhibited by arachidonic acid. CYP2J2 was selected as a candidate expressed in the intestine and closely related to arachidonic acid metabolism. The catalytic activity of recombinant CYP2J2 was much higher than that of CYP4F12. Anti-CYP2J antibody inhibited the hydroxylation to about 70% in human intestinal microsomes. These results demonstrate that CYP2J2 is the predominant ebastine hydroxylase in human intestinal microsomes. Thus, the present paper for the first time indicates that, in human intestinal microsomes, both CYP2J and CYP4F subfamilies not only metabolize endogenous substrates but also are involved in the drug metabolism.

0022-3565/02/3001-0298$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Nucleic Acids ResHome page
N. Hariparsad, X. Chu, J. Yabut, P. Labhart, D. P. Hartley, X. Dai, and R. Evers
Identification of pregnane-X receptor target genes and coactivator and corepressor binding to promoter elements in human hepatocytes
Nucleic Acids Res., March 1, 2009; 37(4): 1160 - 1173.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
W. Albrecht, A. Unger, A. K. Nussler, and S. Laufer
In Vitro Metabolism of 2-[6-(4-Chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] Acetic Acid (Licofelone, ML3000), an Inhibitor of Cyclooxygenase-1 and -2 and 5-Lipoxygenase
Drug Metab. Dispos., May 1, 2008; 36(5): 894 - 903.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Z. Wang, J. Q. Wu, A. S. Bridges, D. C. Zeldin, S. Kornbluth, R. R. Tidwell, J. E. Hall, and M. F. Paine
Human Enteric Microsomal CYP4F Enzymes O-Demethylate the Antiparasitic Prodrug Pafuramidine
Drug Metab. Dispos., November 1, 2007; 35(11): 2067 - 2075.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Z. Wang, J. Y. Saulter, E. Usuki, Y.-L. Cheung, M. Hall, A. S. Bridges, G. Loewen, O. T. Parkinson, C. E. Stephens, J. L. Allen, et al.
CYP4F Enzymes Are the Major Enzymes in Human Liver Microsomes That Catalyze the O-Demethylation of the Antiparasitic Prodrug DB289 [2,5-Bis(4-amidinophenyl)furan-bis-O-methylamidoxime]
Drug Metab. Dispos., December 1, 2006; 34(12): 1985 - 1994.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. Gaedigk, D. W. Baker, R. A. Totah, R. Gaedigk, R. E. Pearce, C. A. Vyhlidal, D. C. Zeldin, and J. S. Leeder
Variability of CYP2J2 Expression in Human Fetal Tissues
J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 523 - 532.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K.-H. Liu, M.-G. Kim, D.-J. Lee, Y.-J. Yoon, M.-J. Kim, J.-H. Shon, C. S. Choi, Y. K. Choi, Z. Desta, and J.-G. Shin
Characterization of Ebastine, Hydroxyebastine, and Carebastine Metabolism by Human Liver Microsomes and Expressed Cytochrome P450 Enzymes: Major Roles for CYP2J2 and CYP3A
Drug Metab. Dispos., November 1, 2006; 34(11): 1793 - 1797.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. F. Paine, H. L. Hart, S. S. Ludington, R. L. Haining, A. E. Rettie, and D. C. Zeldin
THE HUMAN INTESTINAL CYTOCHROME P450 "PIE"
Drug Metab. Dispos., May 1, 2006; 34(5): 880 - 886.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. C. E. McFadyen, W. T. Melvin, and G. I. Murray
Cytochrome P450 enzymes: Novel options for cancer therapeutics
Mol. Cancer Ther., March 1, 2004; 3(3): 363 - 371.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
D. M. Stresser, M. I. Broudy, T. Ho, C. E. Cargill, A. P. Blanchard, R. Sharma, A. A. Dandeneau, J. J. Goodwin, S. D. Turner, J. C. L. Erve, et al.
HIGHLY SELECTIVE INHIBITION OF HUMAN CYP3A IN VITRO BY AZAMULIN AND EVIDENCE THAT INHIBITION IS IRREVERSIBLE
Drug Metab. Dispos., January 1, 2004; 32(1): 105 - 112.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. Matsumoto, T. Hirama, T. Matsubara, K. Nagata, and Y. Yamazoe
Involvement of CYP2J2 on the Intestinal First-Pass Metabolism of Antihistamine Drug, Astemizole
Drug Metab. Dispos., November 1, 2002; 30(11): 1240 - 1245.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.